Filing Flows › Fortress Biotech (FBIO) › Q2 2026
Fortress Biotech (FBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Fortress Biotech (FBIO) reported revenue of $18.7M for the second quarter 2026 (Q2 2026), +14% from a year earlier and +17% from the quarter before. Operating margin was -53.5%, net earnings $602K (3.2% of revenue).
Fortress Biotech, Q2 2026: revenue $18.7M (+14% year over year), operating margin -53.5%, net earnings $602K, operating cash flow −$59.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.7M | +17% | +14% |
| Operating profit | −$10.0M | — | — |
| Net earnings | $602K | -100% | — |
| Operating cash flow | −$59.3M | -129% | — |
What changed
Revenue was $18.7M in Q2 2026, up 14% year over year and up 17% from the previous quarter. Journey was the largest line at 99% of revenue. Journey added $3.5M year over year (up 23%), 152% of the total change.
Operating costs exceeded revenue by $10.0M, an operating margin of -53.5%. Total costs fell 46% while revenue rose 14%. The fastest-growing cost line was Cost of revenue (+24%). Net earnings were −$468K. The effective tax rate was 34.7%. Non-operating items added $10.9M, 1185% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$59.3M. Non-cash charges added back $1.1M of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $63.8M.
Questions
What was Fortress Biotech's revenue in the second quarter 2026?
Fortress Biotech (FBIO) reported revenue of $18.7M for the second quarter 2026 (Q2 2026), +14% from a year earlier and +17% from the quarter before.
Was Fortress Biotech profitable in the second quarter 2026?
Operating loss was $10.0M (-53.5% of revenue) and net earnings $602K.
Source: Fortress Biotech 10-Q on SEC EDGAR.